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ABSTRACT
Objectives To assess whether supplementation with
antioxidants, folinic acid, or both improves the
psychomotor and language development of children with
Down’s syndrome.
Design Randomised controlled trial with two by two
factorial design.
Setting Children living in the Midlands, Greater London,
and the south west of England.
Participants 156 infants aged under 7 months with
trisomy 21.
InterventionDaily oral supplementationwithantioxidants
(selenium 10 μg, zinc 5 mg, vitamin A 0.9 mg, vitamin E
100 mg, and vitamin C 50 mg), folinic acid (0.1 mg),
antioxidants and folinic acid combined, or placebo.
MainoutcomemeasuresGriffithsdevelopmentalquotient
and an adapted MacArthur communicative development
inventory 18 months after starting supplementation;
biochemicalmarkers in bloodandurine at age12months.
Results Children randomised to antioxidant supplements
attained similar developmental outcomes to those
without antioxidants (mean Griffiths developmental
quotient 57.3 v 56.1; adjusted mean difference 1.2
points, 95% confidence interval −2.2 to 4.6). Comparison
of children randomised to folinic acid supplements or no
folinic acid also showed no significant differences in
Griffiths developmental quotient (mean 57.6 v 55.9;
adjusted mean difference 1.7, −1.7 to 5.1). No between
group differences were seen in the mean numbers of
words said or signed: for antioxidants versus none the
ratio of means was 0.85 (95% confidence interval 0.6 to
1.2), and for folinic acid versus none it was 1.24 (0.87 to
1.77). No significant differences were found between any
of the groups in the biochemical outcomes measured.
Adjustment for potential confounders did not appreciably
change the results.
Conclusions This study provides no evidence to support
the use of antioxidant or folinic acid supplements in
children with Down’s syndrome.
Trial registration Clinical trials NCT00378456.
INTRODUCTION
Trisomy 21 (Down’s syndrome) is the most common
genetic cause of learning disability in the United
Kingdom, with a birth prevalence of 1 per 1000 live
births.1 Adults with Down’s syndrome seem to age
prematurely; many show Alzheimer’s-like changes in
their brains in their 30s and 40s.2Neuronal changes are
evident in infantswithDown’s syndrome. Postmortem
studies have reported neuronal depletion and struc-
tural abnormalities of the brain during late gestation
and early postnatal life.3 Why these changes occur is
not fully understood, but involvement of the increased
activity of two enzymes, copper/zinc superoxide
dismutase and cystathionine β-synthase, both coded
for on chromosome 21, has been suggested.
Increased activity of superoxide dismutase in
children with Down’s syndrome is thought to cause
oxidative damage to neuronal cells by increasing
concentrations of hydrogen peroxide.4 Evidence that
oxidative stress may be involved in the premature
neuronal degeneration comes from several sources.
Firstly, the cerebral cortex from fetuses with Down’s
syndrome was found to have increased activity of
superoxide dismutase without a compensatory
increase in glutathione peroxidase activity.5 Secondly,
cortical neurones from fetuses with Down’s syndrome
have an increased concentration of intracellular oxy-
gen derived free radicals and increased lipid peroxida-
tion compared with controls.6 Thirdly, in vitro, fetal
neurones in Down’s syndrome have increased apop-
totic degeneration, which seems to be prevented by the
addition of antioxidants.6 Finally, studies have
reported increased products of lipid peroxidation in
the blood and urine of people with Down’s syndrome
compared with controls.7-10
Evidence for a functional folatedeficiency inDown’s
syndrome is based on analytical studies in plasma and
in vitro studies. The enzyme cystathionine β-synthase
catalyses the condensationofhomocysteinewith serine
to form cystathionine. Increased concentrations of this
enzyme in Down’s syndrome leads to significantly
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reduced plasma concentrations of homocysteine,
methionine, S-adenosylhomocysteine, and S-adenosyl-
methionine and thereby to a “folate trap” and a
functional folate deficiency.11 In vitro studies have
shown that adding selected nutrients (methionine,
folinic acid, methyl B-12, thymidine, and dimethyl-
glycine) to a cultured lymphoblastoid cell line with
trisomy 21 causes a shift in one-carbon metabolism to a
more normal profile.11
Clinical evidence that supplementation with folate,
antioxidants, or both might ameliorate the effects of
Down’s syndrome has been evaluated in a systematic
review.12-14 Four controlled trials of various doses and
combinations of antioxidant vitamin and mineral
supplementation given for three to eight months were
identified in children and young people with Down’s
syndrome.15-19 The trials included a total of 150
participants aged between 6 months and 17 years.
Younger children are thought to be more likely to
benefit from nutritional interventions, but only one
study, a crossover trial with 19 participants, included
children under 5 years of age.16 All the trials have
significant methodological weaknesses, and no meta-
analysis was considered feasible both because of the
heterogeneity of populations and outcomes and
because of a lack of key data in the published papers.
None of the trials reported any significant effect of
antioxidants on cognitive function. Despite these
findings, use of vitamin and mineral supplements is
widespread in children with Down’s syndrome in
Europe and the United States as a result of the
marketing of commercial preparations that claim
substantial benefits for children with Down’s syn-
drome. We aimed to determine the benefits of
supplementation with antioxidants or folinic acid for
psychomotor development and the effect on certain
biochemical markers of oxidative stress.
METHODS
Between May 2002 and February 2004 in Greater
London and the West Midlands and, from January
2003, inNottinghamand the southwest of England,we
enrolled infants aged under 7 months with Down’s
syndrome. We excluded children with chromosome
mosaicism or translocation, severe cardiac defects, or
other serious long term illness and those from non-
English speaking families. We publicised the study
through clinicians and parents’ groups, and we visited
interested families at home. Parents or legal guardians
gave written informed consent. We used a four arm
factorial design to randomise infants to receive a daily
oral dose of antioxidants (selenium 10 μg, zinc 5 mg,
vitamin A 0.9 mg, vitamin E 100 mg, and vitamin C
50mg), folinic acid (0.1mg), a combination of the same
doses of antioxidants and folinic acid, or a placebo
(mannitol, malodextrin, and a natural food colour). All
combinations were powders that appeared identical
and could be mixed with food or drink. Pharmacists,
who retained the allocation lists, allocated participants
according to a randomsequence generatedby aMinim
computer programme with minimisation for sex and
presence of congenital heart disease. Supplements
were prepared and packaged as identical sachets by
Quintiles (Edinburgh), stored in the pharmacy, and
mailed directly to the parents.We showed parents how
to mix and administer the supplements at the enrol-
ment visit, and the dosage was increased by 30% after
the child’s first birthday.Researcherswerenot awareof
treatment allocation until the analyses were complete.
Parents were blind to allocation until after the final
outcome assessment but could thereafter request
information directly from the pharmacy.
Todetect a clinically important difference of 6 points
on the Griffiths mental developmental quotient
(equivalent to 0.5 of a standard deviation) with 85%
power we needed 68 patients in each combined
treatment group (antioxidants v no antioxidants and
folinic acid vno folinic acid).Weplanned to recruit 200
infants, allowing for a 33% loss to follow-up.
We monitored compliance with supplements in two
ways. Firstly, at each visit or telephone call, we asked
parents how many doses had been missed in the
previous nine months. Secondly, we collected blood
samples at approximately 1 year of age to measure
plasma vitaminE concentrations.We collected venous
samples into lithium heparin tubes, separated within
three to four hours of collection and stored at −80°C
before analysis. We measured plasma vitamin E
(α-tocopherol) with high performance liquid chromato-
graphy with fluorimetric detection by a modification of
the method of Buttriss and Diplock.2021 We expressed
vitamin E concentrations per millimole of plasma
cholesterol, measured enzymatically on a COBAS
Assessed for eligibility (n=215)
Randomised (n=156)
Group A
Assigned to antioxidants
and folinic acid (n=41)
Group B
Assigned to
antioxidants only (n=40)
Group C
Assigned to folinic
acid only (n=36)
Group D
Assigned to
placebo (n=39)
Analysed (n=37)
Griffiths scales (n=36)
S and L (n=37)
Milestones (n=36)
(Including 6 who
stopped taking
supplements)
Analysed (n=37)
Griffiths scales (n=37)
S and L (n=36)
Milestones (n=34)
(Including 9 who
stopped taking
supplements)
Analysed (n=32)
Griffiths scales (n=32)
S and L (n=32)
Milestones (n=31)
(Including 1 who
stopped taking
supplements)
Analysed (n=33)
Griffiths scales (n=33)
S and L (n=33)
Milestones (n=32)
(Including 1 who
stopped taking
supplements)
Excluded (n=59):
  Did not meet inclusion criteria (n=23)
  Refused to participate (n=30)
  Other (n=6)
Lost to follow-up
  (n=6):
    Leukaemia
      (n=1)
    Moved abroad
      (n=3)
    Lost contact
      (n=2)
Lost to follow-up
  (n=4):
    Died (n=2)
    Leukaemia
      (n=1)
    Lost contact
      (n=1)
Lost to follow-up
  (n=3):
    Moved abroad
      (n=1)
    Lost contact
      (n=2)
Lost to follow-up
  (n=4):
    Died (n=1)
    Leukaemia
      (n=1)
    Lost contact
      (n=2)
Trial profile. S and L=speech and language
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Fara analyser with a kit supplied by ABX Diagnostics
(Montpelier, France).22
Developmental outcomes
One of four trained assessors measured the primary
outcome, age adjusted general quotient on theGriffiths
mental developmental scales (birth to 2 years, 1996
revised version), 18 months after enrolment. The
Griffiths scales combine observations on how the
child interacts with test equipment, together with
developmental questions to parents. The number of
“successes” the child achieves is converted to a
developmental age equivalent. Scores are also pro-
duced on five subsections (locomotor, personal-social,
hearing and language, coordination, and perfor-
mance), and age adjusted subquotients are calculated.
Parents used a diary to prospectively record the date
their child achieved major motor milestones such as
sitting without support and walking. Missing records
were completed on the basis of parental recall at visits
nine and 18 months after enrolment. We used Cox
regression to estimate treatment differences in
recorded age of attainment of milestones.
We assessed language development with a modified
version of the MacArthur communicative develop-
ment inventory, a five section postal questionnaire.23
As this was designed for theUnited States, we replaced
the standard word list (section B) with one used for UK
children24; we administered it to the parents at the
18 month home visit. We scored signed as well as
spoken words and calculated the total number of
gestures; phrases understood; and words said, signed
and said, or signed. We adjusted the results for age.
Biochemical outcomes
We determined whether supplementation had any
detectable effect on the antioxidant enzymes copper/
zinc superoxide dismutase and glutathione peroxidase in
redbloodcells.Wemeasured superoxidedismutasewith
theRANSODkit, which is based on the originalmethod
of McCord and Fridovich.25 We measured glutathione
peroxidise with the RANSEL kit, which is based on the
methodof Paglia andValentine.26We ranboth assays on
a COBAS Fara analyser, and Randox Laboratories
(County Antrim) supplied the RANSOD and RANSEL
kits. We expressed both superoxide dismutase and
Table 1 | Characteristics of trial participants at baseline. Values are numbers (percentages) unless stated otherwise
Characteristics
Group A:
antioxidants and
folinic acid (n=41)
Group B:
antioxidants only
(n=40)
Group C: folinic
acid only (n=36)
Group D: placebo
(n=39)
A+B+C+D total
(n=156)
Infants
Mean (range) age (months) 4.1 (0.4-6.3) 4.3 (1.2-6.2) 4.6 (1.5-6.8) 3.7 (1.3-6.9) 4.15 (0.4-6.9)
Mean (range) age of assessment
(months)
Mean (range) birth weight (kg) 2.8 (0.9-4.1) 2.8 (1.4-4.3) 2.8 (1.1-3.8) 2.8 (1.3-4.5) 2.8 (0.9-4.5)
First born 17 (41) 17 (43) 15 (42) 19 (49) 68 (44)
Male sex 23 (56) 24 (60) 21 (58) 21 (54) 89 (57)
Neonatal intensive care unit:
Admitted 14 (34) 24 (60) 16 (44) 15 (38) 69 (44)
Ventilated 4 (10) 3 (8) 5 (14) 4 (10) 16 (10)
Congenital heart disease:
Cyanotic heart disease* 7 (17) 5 (13) 2 (6) 4 (10) 18 (12)
Ventricular septal defect 4 (10) 6 (15) 7 (19) 3 (8) 20 (13)
Drugs for cardiac failure 6 (15) 2 (5) 4 (11) 2 (5) 14 (9)
Families
Mean (range) maternal age (years) 32.8 (19.0-44.0) 34.7 (19.0-44.0) 34.8 (20.0-46.0) 33.0 (20.0-46.0) 33.8 (19.0-46.0)
Social class:
1 (highest) 19 (46) 20 (50) 16 (44) 14 (36) 69 (44)
2 8 (20) 11 (28) 9 (25) 11 (28) 39 (25)
3 10 (24) 4 (10) 11 (31) 13 (33) 38 (24)
4 (lowest) 4 (10) 5 (13) 0 (0) 1 (3) 10 (6)
Maternal ethnicity:
White 26 (63) 28 (70) 27 (75) 31 (80) 112 (72)
Black 4 (10) 6 (15) 3 (8) 4 (10) 17 (11)
Asian 7 (17) 5 (13) 1 (3) 2 (5) 15 (9)
First language English 31 (76) 32 (80) 31 (86) 36 (92) 130 (83)
Area resident
Midlands 17 (41) 14 (35) 5 (14) 19 (49) 55 (35)
London 18 (44) 23 (58) 23 (64) 17 (43) 81 (52)
South west England 6 (15) 3 (7) 8 (22) 3 (8) 20 (13)
*Includes children with atrioventricular septal defect or Fallots tetralogy.
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glutathione peroxidase activities per milligram of hae-
moglobin measured as cyanmethaemoglobin.
Wemeasured urinary isoprostane concentrations as a
marker of lipid peroxidation. We extracted the isopros-
taneswith a specific affinity sorbent supplied byCayman
Chemicals Company (Ann Arbor, USA) and estimated
concentrations with gas chromatography-mass spectro-
metry by amodification of themethod of Bessard et al,27
using the deuterated compound as an internal standard.
The mass spectrometer was operated in the selected ion
monitoring mode with ions at m/z 481 and 485
(deuterated compound used for quantification). We
expressed concentrations of isoprostane per millimole
of urinary creatinine, which was measured with a
COBAS Fara analyser and a kit supplied by ABX
Diagnostics (Montpelier, France), based on the Jaffe
reaction.28
Analyses
We based all analyses on the intention to treat principle.
In the primary analyses, we compared children who
received antioxidants with those who did not and those
who received folinic acid with those who did not. For
continuous variables, we used regression analyses to
estimate the differences between groups for each inter-
vention and their confidence intervals, adjusted for the
effect of the other intervention, area of residence, and
baseline stratification variables.29 For dichotomous vari-
ables, we used logistic regression analyses to produce
similarly adjusted estimates of the odds ratios and
confidence limits. Where these measures were not age
standardised, we adjusted for age at assessment. We log-
transformed the number of words said, signed, or said or
signed to ensure approximate normality of the residuals.
We thenexpressedeffect sizes as ratios ofmeans adjusted
for the effect of the other intervention, area of
residence, and the baseline stratification variables.29 In
secondary analyses, we further adjusted for variation in
age, maternal ethnicity, social class, and neonatal
problems. We also tested for an interaction between the
interventions.
RESULTS
Enrolment, follow-up, and compliance
In all, 215 families were referred to the research team, of
whom 59 either did not meet the inclusion criteria or
declined to participate; 156 infants (mean corrected age
4.2 months) were randomly assigned to one of four
groups (figure). We abandoned the planned sample size
of 200 infants because of slow recruitment and funding
restrictions. Baseline characteristics were similar in the
four groups, although a larger proportion of children in
group B than in other groups had been admitted to a
neonatal intensive care unit (the proportion needing
ventilationwassimilar,however)andgroupCincludeda
smaller proportion of children from the Midlands and
more from the south west (table 1)
Of the 17 (11%) children lost to follow-up, threedied,
three developed leukaemia, and four moved abroad.
The mean age at completion of the trial was 22.
9 months (range 18.6-35.9 months). We assessed 139
children for the primary outcome of Griffiths devel-
opmental quotient after 18 months. The figure shows
follow-up for other outcomes.
More of the children taking antioxidants than taking
folinic acid alone or placebo stopped taking supple-
ments (15/74, 20% v 2/65, 3%; relative risk 6.5, 95%
confidence interval 1.5 to 27). Only children taking
antioxidants stopped supplements because of vomiting
or distress (10/74 v 0/65; P=0.002). No other notable
adverse events were reported. For the children who
continued on supplements, reported compliance was
good; 78% (94/122) of parents reported missing fewer
than 10% (<54/547 days) of daily doses, and only 6/
122 (4%) missed more than 20% of doses (>104/
547 days). We measured mean plasma vitamin E per
millimole of cholesterol in 95 children, and this was
almost twice as high in those taking antioxidants as in
those taking placebo or folinic acid alone (10.76 v 5.92
µmol/mmol cholesterol; P<0.0001).
At the end of the trial, we asked parents to guess
which of the four supplements their child had been
taking during the trial. Only 44/138 (32%) parents felt
able to guess, and of these only 11/44 (25%) guessed
correctly, which is consistent with chance.
Effects on development
We found no evidence for clinically or statistically
significant effects of antioxidants or folinic acid on any
of the outcomes measured. Table 2 shows the
unadjusted mean Griffiths developmental quotients
by group. Table 3 shows results for clinical and
biochemical outcomes, adjusted for variables used to
stratify randomisation. We found no significant differ-
encesbetweengroups randomisedandnot randomised
to antioxidants or between those randomised and not
randomised to folinic acid on Griffiths developmental
quotient or measures of language (table 3).
Supplementation also had no effect on the recorded
age at attainment of motor milestones. Comparing
infants allocated to antioxidants with those who were
not, thehazardratio forageof sittingwithoutsupportwas
1.10 (95% confidence interval 0.77 to 1.56) and that for
standing was 1.25 (0.88 to 1.78). The results for children
on folinic acid compared with those not on folinic acid
were 1.25 (0.88 to 1.78) for sitting and 1.14 (0.76 to 1.71)
for standing. None of these results changed appreciably
Table 2 | Unadjustedmeans*ofGriffithsdevelopmentalquotient forall combinationsofgroups in
factorial design
Antioxidants
Folinic acid
TotalYes No
Yes: (Group A; n=36) (Group B; n=37) (Group A+B; n=73)
Mean GQ 58.7 (9.3) 57.4 (9.8) 58.0 (1.1)
No: (Group C; n=32) (Group D; n=33) (Group C+D; n=65)
Mean GQ 57.8 (11.9) 56.1 (9.8) 56.9 (1.3)
Total: (Group A+C; n=68) (Group B+D; n=70) (Group A+B+C+D; n=138)
Mean GQ 58.3 (1.3) 56.8 (1.2) 57.5 (0.9)
GQ=general quotient; group A=antioxidants and folinic acid; group B=antioxidants only; group C=folinic acid
only; group D=placebo.
*Standard deviations in parentheses for individual group entries; standard errors shown for entries for totals.
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after adjustment forareaof residence,maternal ethnicity,
birth weight, and social class.
Enzyme activities and oxidative stress
We obtained blood at 1 year of age from 107 children
and measured enzyme activities on 99 samples. We
obtained urine from 106 children and estimated
isoprostane concentrations in 52. We found no
significant effect of antioxidant or folinic acid supple-
mentation on superoxide dismutase or glutathione
peroxidase activities or on the superoxide dismutase to
glutathione peroxidase ratio or urinary isoprostane
concentrations (table 3)
DISCUSSION
We found no evidence that either the antioxidants or
the folinic acid supplements used in this trial had any
effect on psychomotor development or language
acquisition in children with Down’s syndrome. Activ-
ities of the antioxidant enzymes (red cell superoxide
dismutase, red cell glutathioneperoxidase) andurinary
isoprostane concentrations (a marker of lipid perox-
idation) were similar in all groups, indicating that
supplementation did not affect oxidative stress.
These findings are supported by a systematic review
that included four randomised controlled trials of high
dose vitamin supplements compared with placebo.14
Concerns that thedesignofprevious studies couldhave
biased in favourof noeffect, owing to small sample size,
short duration of supplementation (3-8 months), and
late ageof starting supplements,were considered inour
study. Our sample size was sufficient to detect a
clinically small effect in the main developmental
outcome (6 Griffiths developmental quotient points),
and loss to follow-upwasonly11%. Infantswere started
on supplements at a mean age of 4 months and
Table 3 | Developmental, speech, andbiochemical outcomes for children randomised to antioxidants versus no antioxidants or to folinic acid versusno folinic acid.
Values aremean (SD) unless statedotherwise
Outcomes
Antioxidants v no antioxidants Folinic acid v no folinic acid
Group A+B Group C+D
Mean difference or ratio of
means (95% CI) Group A+C Group B+D
Mean difference or ratio of
means (95% CI)
Griffiths mental developmental scales*
Number 73 65 – 68 70 –
Total GQ 58.1 (9.5) 56.9 (10.8) 1.2 (−2.2 to 4.6) 58.4 (10.5) 56.7 (9.7) 1.7 (−1.7 to 5.1)
Griffiths subscales*:
Locomotor 54.1 (12.0) 51.1 (12.5) 3.0 (−1.1 to 7.0) 53.1 (11.6) 52.3 (12.9) 0.9 (−3.2 to 5.0)
Personal-social 62.6 (12.9) 61.5 (13.2) 1.1 (−3.2 to 5.4) 62.7 (12.5) 61.5 (13.5) 1.2 (−3.2 to 5.6)
Hearing and language 56.5 (10.3) 56.8 (14.3) −0.3 (−4.5 to 3.9) 56.9 (11.6) 56.3 (12.9) 0.6 (−3.6 to 4.9)
Eye and hand 61.9 (11.6) 60.9 (12.3) 1.0 (−3.0 to 5.1) 62.6 (12.9) 60.2 (10.7) 2.3 (−1.8 to 6.4)
Performance 60.8 (15.7) 59.3 (15.5) 1.5 (−3.8 to 6.8) 61.8 (16.5) 58.5 (14.6) 3.3 (−2.1 to 8.6)
Receptive language†
Number 73 65 – 69 69 –
Total gesture score 31.3 (11.9) 32.4 (11.4) −1.1 (−5.1 to 2.9) 32.0 (11.2) 31.7 (12.1) 0.3 (−3.8 to 4.4)
Phrases understood 15.7 (6.6) 16.5 (7.4) −0.8 (−3.2 to 1.6) 16.3 (6.8) 15.8 (7.2) 0.5 (−2.0 to 2.9)
Expressive language‡
Number 73 65 – 69 69 –
Mean No of words child says§ 3.2 (3.6) 4.9 (6.3) 0.82 (0.60 to 1.12) 4.7 (6.2) 3.4 (3.7) 1.05 (0.76 to 1.45)
Mean No of words child signs§ 6.0 (7.8) 6.1 (7.6) 0.93 (0.66 to 1.31) 7.2 (8.5) 4.9 (6.5) 1.33 (0.93 to 1.89)
Mean No of words child says or
signs§
8.2 (8.3) 9.7 (9.6) 0.86 (0.61 to 1.21) 10.4 (9.9) 7.3 (7.7) 1.24 (0.87 to 1.77)
Blood analysis¶
Number 52 47 – 50 49 –
Superoxide dismutase (SOD-1) (U/
mg Hb)
4.0 (1.1) 3.8 (1.1) 0.2 (−0.2 to 0.6) 3.9 (1.2) 3.9 (0.9) 0.1 (−0.4 to 0.5)
Glutathione peroxidise (GSH-Px) (U/
mg Hb)**
66.3 (34.8) 65.3 (37.7) 4.2 (−9.3 to 17.7) 71.7 (41.4) 60.2 (29.4) 7.6 (−6.0 to 21.3)
Ratio of SOD-1 to GSH-Px§†† 0.077 (0.06) 0.077 (0.05) 0.99 (0.79 to 1.24) 0.077 (0.06) 0.077 (0.04) 1.01 (0.81 to 1.27)
Urine analysis¶
Number 26 26 – 23 29 –
Isoprostanes§ (pmol/mmol
creatinine)
2264 (2202) 2306 (2399) 1.10 (0.61 to 2.00) 2243 (2143) 2318 (2419) 0.92 (0.52 to 1.61)
GQ=general quotient; group A=antioxidants and folinic acid; group B=antioxidants only; group C=folinic acid only; group D=placebo; Hb=haemoglobin.
*Mean (SD) and confidence interval adjusted for area of residence, sex, and congenital heart disease.
†Mean (SD) and confidence interval adjusted for area of residence, age, sex, and congenital heart disease.
‡Unadjusted mean (SD); confidence interval adjusted for area of residence, age, sex, and congenital heart disease.
§Mean difference calculated on log scale and back transformed to give ratio of means on original scale.
¶Unadjusted mean (SD); confidence interval adjusted for area of residence, sex, and congenital heart disease.
**After exclusion of outlier with GSH-Px of 312.
††After exclusion of outlier with SOD:GSH-Px ratio of 6.4.
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continued for 18 months. Reported compliance was
good and confirmed by increased plasma vitamin E
concentrations in those children on supplementation.
Concealment of allocation was good, and blinding
proved to be effective as only 8% of parents correctly
guessed which supplement their child was taking.
One limitation of our study was the relatively low
dose of supplements compared with commercially
available preparations (Nutrivene-D and Euro TNI),30
whichmay have been inadequate to affect biochemical
pathways.Thedosesused in the studywere100%of the
recommended daily allowance for vitamin E, zinc, and
selenium and 200% of the recommended daily
allowance for vitamin C and folinic acid.31 We were
reluctant to use higher doses, as data on the safety of
highdoses foryoungchildrenare lackingandhighdose
vitaminCmay in fact exhibit pro-oxidant properties.32
Our results do not exclude the possibility that subtle
effects of supplementation on development might be
detectable given longer term supplementation and
follow-up.
The mechanisms responsible for the neuronal
changes inDown’s syndrome are likely to be complex.
Superoxide dismutase and cystathionine β-synthase
are just two of many gene products coded for on
chromosome 21. The variable phenotype of Down’s
syndrome could result from an interaction involving
any of the genes or gene products coded on this
chromosome.33 An aneuploid mouse strain carrying
human chromosome 21 has recently been developed,
and this might provide further insights into the
complex mechanisms involved in Down ’s
syndrome.34
As Down’s syndrome has a profound effect on the
lives of children and their families, parents will
probably have a low threshold for trying interventions.
Commercially available nutritional supplements cost
between £15 and £30 (€20-40; $30-60) amonth, and, as
they are food supplements, they do not have to be
produced to the same high standards as prescription
drugs. The only short term side effect we found was a
significant increase in vomiting in infants taking
antioxidants, but the side effects of higher dose
preparations used over a long period are unknown.
The widely held belief that vitamins are harmless has
been challenged by a recent systematic review and
meta-analysis of controlled trials, which suggested that
antioxidant supplementation is associated with
increased mortality across a range of conditions.35 36
Conclusion
Our study provides no evidence to support the use of
antioxidants or folinic acid in young children with
Down’s syndrome. Parents who choose to give
supplements to their children need to weigh their
hope of unproved benefits against potential adverse
effects from high dose, prolonged supplementation.
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